Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

Block GA, Hulbert-Shearon TE, Levin NW, Port FK.

Am J Kidney Dis. 1998 Apr;31(4):607-17.

PMID:
9531176
3.
4.

Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD).

Qunibi WY.

Kidney Int Suppl. 2004 Sep;(90):S8-S12. Review.

PMID:
15296501
5.

Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon.

Qunibi WY, Nolan CA, Ayus JC.

Kidney Int Suppl. 2002 Dec;(82):S73-80. Review.

6.

Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.

Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA.

Am J Kidney Dis. 2016 Nov;68(5S1):S24-S32. doi: 10.1053/j.ajkd.2016.05.024. Review.

PMID:
27772640
7.

Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF.

JAMA. 2011 Mar 16;305(11):1119-27. doi: 10.1001/jama.2011.308. Review.

PMID:
21406649
9.

Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.

Lorenzo Sellares V, Torres Ramírez A.

Drugs Aging. 2004;21(3):153-65. Review.

PMID:
14979734
10.
11.

Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis.

Natoli JL, Boer R, Nathanson BH, Miller RM, Chiroli S, Goodman WG, Belozeroff V.

BMC Nephrol. 2013 Apr 17;14:88. doi: 10.1186/1471-2369-14-88. Review.

12.

Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.

Palmer SC, Teixeira-Pinto A, Saglimbene V, Craig JC, Macaskill P, Tonelli M, de Berardis G, Ruospo M, Strippoli GF.

Am J Kidney Dis. 2015 Dec;66(6):962-71. doi: 10.1053/j.ajkd.2015.03.036. Epub 2015 May 21. Review.

13.

Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.

Molony DA, Stephens BW.

Adv Chronic Kidney Dis. 2011 Mar;18(2):120-31. doi: 10.1053/j.ackd.2011.02.004. Review.

PMID:
21406297
14.

[Importance of the "adequate blood phosphorus" concept as a risk factor for hyperphosphatemia].

Douthat WG, Alles A, Marinovich S, Tirado S, Peñalba A, Prudkin S.

Nefrologia. 2003;23 Suppl 2:95-9. Review. Spanish.

15.

The role of daily dialysis in the control of hyperphosphatemia.

Achinger SG, Ayus JC.

Kidney Int Suppl. 2005 Jun;(95):S28-32. Review.

16.

Understanding and managing hyperphosphatemia in patients with chronic renal disease.

Malluche HH, Monier-Faugere MC.

Clin Nephrol. 1999 Nov;52(5):267-77. Review.

PMID:
10584989
17.

Phosphate restriction in diet therapy.

Takeda E, Yamamoto H, Nishida Y, Sato T, Sawada N, Taketani Y.

Contrib Nephrol. 2007;155:113-24. Review.

PMID:
17369719
18.

Treatment options for hyperphosphatemia in feline CKD: what's out there?

Kidder AC, Chew D.

J Feline Med Surg. 2009 Nov;11(11):913-24. doi: 10.1016/j.jfms.2009.09.012. Review.

PMID:
19857854
19.

Phosphorus Regulation in Chronic Kidney Disease.

Suki WN, Moore LW.

Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4 Suppl):6-9. doi: 10.14797/mdcj-12-4s1-6. Review.

20.

Supplemental Content

Support Center